BioSpace News Archive

Erasca, Inc. (Nasdaq: ERAS) today announced the publication of results in the Journal of Clinical Oncology from the expansion arm of a Phase 1b open label study evaluating pan-RAF inhibitor naporafenib plus MEK inhibitor trametinib (MEKINIST®) in patients with NRAS-mutant (NRASm) melanoma.

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company’s Chief Executive Officer, Talat Imran, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023 at 11:30 am E.T.

Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2023.

Cue Biopharma, Inc. announced today the appointment of seasoned pharmaceutical executive Pamela D. Garzone, Ph.D., to its board of directors.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that the Company will release its first quarter 2023 financial results on Monday, May 15, 2023.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, announces FDA orphan drug designation for INB-400 and INB-410, covering a broad range of malignant glioma treatments, including newly diagnosed GBM.

Guardant Health, Inc. and the Parker Institute for Cancer Immunotherapy (PICI) today announced a research collaboration agreement to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across more than 14 different types of cancer.

Myrtelle Inc today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA), the healthcare regulatory body of the United Kingdom (UK), granted Innovative Licensing and Access Pathway (ILAP) designation to the Company’s lead gene therapy product candidate, rAAV-Olig001-ASPA for the treatment of Canavan disease.

Health Catalyst, Inc., a leading provider of data and analytics technology and services to healthcare organizations, will release its first quarter 2023 operating results on Tuesday, May 9, 2023, after market close.

Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”) today announced that it has signed a new three-year agreement with Boston IVF, a pioneer in reproductive healthcare and innovative research and one of the world’s most experienced fertility treatment providers.